Brand and Other Names:Bumex, Burinex
- Classes: Diuretics, Loop
Dosing & Uses
Dosage Forms & Strengths
PO: 0.5-2 mg once; may be repeated in 4-5 hours for up to 2 doses; not to exceed 10 mg/day
IM: 0.5-1 mg once; may be repeated in 2-3 hours for up to 2 doses; not to exceed 10 mg/day
IV: 1 mg initially, then 0.5-2 mg/hr
I mg IV loading dose, then 0.5-2 mg/day PO divided q12hr
1 mg bumetanide is roughly equivalent to 40 mg furosemide
Edema due to congestive heart failure, hepatic disease, or nephrotic syndrome
- Use with fluid retention refractory to thiazides or with impaired renal function
- May be tried if patient is allergic to furosemide
- Normal saline may be used for volume replacement
- Dopamine or norepinephrine may be used to treat hypotension
- Treat hyperkalemia with IV glucose (D25W) with rapid-acting insulin and concurrent IV sodium bicarbonate; use oral or rectal solutions of sodium polystyrene in sorbitol if needed
- If dysrhythmia due to decreased potassium or magnesium is suspected, replace aggressively
- Discontinue treatment if no symptoms are apparent after 6 hours
Dosage Forms & Strengths
In general, dosage selection for elderly should be cautious, usually starting at low end of dosing range, in view of higher incidence of decreased hepatic, renal, or cardiac function and greater frequency of concomitant disease or other drug therapy
Serious - Use Alternative
Significant - Monitor Closely
Increased serum creatinine (7%)
Variations in phosphorus (5%)
Variations in CO2 content (4%)
Variations in bicarbonate (3%)
Variations in calcium (2%)
Muscle cramps (1%)
Serious skin reactions (ie, Stevens-Johnson syndrome, toxic epidermal necrolysis)
Black Box Warnings
Agent is potent diuretic that, if given in excessive amounts, may lead to profound diuresis with water and electrolyte depletion
Careful medical supervision is required; dosing must be adjusted to patient's needs
Documented hypersensitivity to bumetanide or sulfonamides
Severe uncorrected electrolyte depletion, anuria, hepatic coma
Risk of electrolyte imbalance, alterations in glucose metabolism, blood dyscrasias, development of oliguria or increased blood urea nitrogen (BUN) or creatinine, hepatic disease, hyperuricemia, hypokalemia, hypomagnesemia, hypovolemia, neonates at risk for kernicterus
Risk of ototoxicity with rapid IV administration
Fluid status and renal function should be monitored to prevent oliguria, increased creatinine and BUN, and azotemia
Asymptomatic hyperuricemia is reported
Use with caution in patients with cirrhosis
Coadministration with antihypertensive agent may increase risk of hypotension
Pregnancy & Lactation
Pregnancy category: C
Lactation: Unknown whether drug is excreted in breast milk; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Inhibits reabsorption of sodium and chloride in ascending loop of Henle, thereby causing excretion of water and sodium, chloride, calcium, magnesium, potassium, and hydrogen ions
Onset: IV, 2-3 min; PO/IM, 30-60 min
Duration: 4-6 hr
Peak plasma time: IV, 5 min; IM, 30 min; PO, 1-2 hr
Protein bound: 94-96%
Vd: Adults, 9-25 L; neonates and infants, 0.26-0.39 L/kg
Partially metabolized in liver
Metabolites: Bumetanide conjugates, desbutyl bumetanide, primary alcohols, aliphatic acid metabolite (inactive)
Half-life: Adults, 1-1.5 hr; infants >1 month, 2.4 hr; neonates, 6 hr
Excretion: Urine (81%), feces (2%)
Y-site: Fenoldopam, midazolam
Additive: Floxacillin, furosemide
Y-site: Check with manufacturer
May be administered by IM injection, by IV injection over 1-2 minutes, or by IV infusion
If glass ampoules are used, filter to remove particles
Store at room temperature
Protect from light; drug discolors when exposed to light
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs